Market Cap 8.40B
Revenue (ttm) 4.07B
Net Income (ttm) 560.12M
EPS (ttm) N/A
PE Ratio 44.72
Forward PE 78.51
Profit Margin 13.77%
Debt to Equity Ratio 1.45
Volume 560,162
Avg Vol 698,186
Day's Range N/A - N/A
Shares Out 60.66M
Stochastic %K 83%
Beta 0.28
Analysts Strong Sell
Price Target $187.81

Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymp...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 634 7800
Address:
Waterloo Exchange, Fifth Floor Waterloo Road Dublin 4, Dublin, Ireland
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 24 at 4:42 PM
$SLS $CPXX was a great Illustration of what will be happening here. it was a Puny $50M mcap $1.68 when it released its AML Phase 3 Trial Results. It Gapped up to $250M +500% that Day, kept climbing to to $750M mcap and then got bought for $1.5B +1,600% in 2 months, based on P3 trial results, that told the whole market and $JAZZ that it was for sure getting FDA Approval and going to generate REAL REVENUE. Ps... SLS009 is a direct head to head competitive treatment in the AML-MR segment. You can See CPXX was approved w 9.59 months of OS in FRONT LINE / NEWLY dxd AML-MR patients - SLS009 p2 OS of 9 months in END STAGE AML-MR. Just 009 is worth worth 10x the current market cap. and the P3 is fully funded SLS has $68M in Cash / $6.7M q Burn / runway into 2027 - no Offerings needed /Allowed per S3 through Jan.
0 · Reply
ReapN
ReapN Oct. 24 at 4:03 PM
$SLS setting up comparison $CPXX Celator $JAZZ M&a Celator who is SEllas suitoR(s)? Add low Hold Sell when its time
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 23 at 6:19 PM
$SNDX FY2026 & 10-year revenue multiple versus all commercial-stage oncology focused bios with market caps over $1.0B. SNDX's cumulative 10-year analyst revenue estimate excludes the highest revenue forecast for all 10-years. Using actual analyst consensus, SNDX trades at 0.12X 10-year revenues. Valuations use intra-day share prices on 10/23/2025 $IBRX trades at the 2nd lowest multiple. However, we understand IBRX needs future clinical wins to realize those estimates. We are not 100% certain $PGEN belongs in this peer group. Any suggestions would be welcome. $JAZZ multiples use enterprise value. $NVCR also appears a value using analyst estimates & multiples versus peers. We understand ST users express doubts on whether analyst estimates are credible in light of lung related sales to date. This is not investment advice.
3 · Reply
Quantumup
Quantumup Oct. 22 at 7:09 PM
RBC Capital⬆️ $ALKS's PT to $ 47 from $45, reiterated at Outperform, and said, Following the announcement of ALKS's intention to acquire $AVDL, we had the chance to catch up with ALKS mgmt. $JAZZ $CNTA $AXSM RBC Capital added: We think the acquisition checks multiple boxes — supporting a key future growth driver with a commercial base of operations, bringing in near-term revenues, and not stretching the balance sheet — and we think bringing in AVDL should strengthen both the near- and mid-term outlook for ALKS. We continue to like the setup into VIBRANCE-2 where we see potential for high efficacy and good tolerability, and with the base business performing well, and a new growth driver added, we would be buyers at these levels; price target to $47.X on model updates as we integrate AVDL.
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 22 at 12:50 PM
$AVDL (+3.7% pre) Avadel settles with $JAZZ Jazz Pharma; agrees to be acquired by $ALKS Alkermes https://ooc.bz/l/81384
0 · Reply
Rekin_rouge
Rekin_rouge Oct. 22 at 11:58 AM
$AVDL It’s the end of the journey for $AVDL. Learned a lot from this one — got in around $2.2 back then. Was already out before today, but still a bit disappointed by the takeover price and the weak JAZZ settlement. Expected a real hit for $JAZZ and $AVDL to run toward $40. Anyway, it’s been a ride.
1 · Reply
CUBBY91
CUBBY91 Oct. 21 at 5:37 PM
$JAZZ big volume today and a really nice technical set up. is there any news?
0 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 3:36 PM
Morgan Stanley has adjusted their stance on Jazz Pharmaceuticals ( $JAZZ ), setting the rating to Overweight with a target price of 167 → 180.
0 · Reply
twiggs462
twiggs462 Oct. 19 at 12:56 AM
$ATAI $MNMD Remember that $JAZZ bought our $GWPH in 2021 for 7.2B for their epilepsy drug Epidiolex. I realize that ATAI wants to run on their own, but its always possible for them to partner and get in lock step with a big player. Both them and MindMed could get bought out.
1 · Reply
Its_Only_Money_369
Its_Only_Money_369 Oct. 17 at 10:37 PM
$AVDL $JAZZ Since yaho wont let me post it and Jazz board will bury it with 10x average message volume ill post it here. If I were representing Avadel I would subpoena someone from each of the following. FDA, FTC, DOJ and Missouri Attorney Generals office. Not just because they would provide valuable testimony but because I’m sure some of them already have reserved seats. It would also prevent them from turning a blind eye to the issues they are obligated to oversee and address. Win or lose, the best angle for Avadel would be to make sure lack of oversight by those agencies is not an option. Multiple antitrust claims and at least one settlement outside of court involving Jazz monopolistic approach to Oxybate.
2 · Reply
Latest News on JAZZ
US FDA approves Jazz Pharma's therapy for lung cancer

Oct 2, 2025, 3:37 PM EDT - 25 days ago

US FDA approves Jazz Pharma's therapy for lung cancer


US FDA approves Jazz Pharma's drug for rare brain tumor

Aug 6, 2025, 3:00 PM EDT - 2 months ago

US FDA approves Jazz Pharma's drug for rare brain tumor


Is JAZZ Stock Undervalued At $110?

Jul 7, 2025, 10:05 AM EDT - 4 months ago

Is JAZZ Stock Undervalued At $110?


Jazz Pharmaceuticals: One Step Forward, One Back

May 21, 2025, 4:58 AM EDT - 5 months ago

Jazz Pharmaceuticals: One Step Forward, One Back


Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:06 PM EDT - 6 months ago

Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript


Jazz Pharmaceuticals Completes Acquisition of Chimerix

Apr 21, 2025, 4:05 PM EDT - 6 months ago

Jazz Pharmaceuticals Completes Acquisition of Chimerix


Jazz Pharmaceuticals to buy Chimerix for $935 million

Mar 5, 2025, 7:14 AM EST - 8 months ago

Jazz Pharmaceuticals to buy Chimerix for $935 million

CMRX


Jazz Pharmaceuticals plc (JAZZ) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 9:20 PM EST - 8 months ago

Jazz Pharmaceuticals plc (JAZZ) Q4 2024 Earnings Call Transcript


3 Biotech Stocks With Notable Insider Buying

Jan 22, 2025, 12:29 PM EST - 9 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT ONC XBI ZYME


3 Oversold Biotech Names

Jan 13, 2025, 12:56 PM EST - 10 months ago

3 Oversold Biotech Names

AVDL FOLD VKTX XBI


Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 24 at 4:42 PM
$SLS $CPXX was a great Illustration of what will be happening here. it was a Puny $50M mcap $1.68 when it released its AML Phase 3 Trial Results. It Gapped up to $250M +500% that Day, kept climbing to to $750M mcap and then got bought for $1.5B +1,600% in 2 months, based on P3 trial results, that told the whole market and $JAZZ that it was for sure getting FDA Approval and going to generate REAL REVENUE. Ps... SLS009 is a direct head to head competitive treatment in the AML-MR segment. You can See CPXX was approved w 9.59 months of OS in FRONT LINE / NEWLY dxd AML-MR patients - SLS009 p2 OS of 9 months in END STAGE AML-MR. Just 009 is worth worth 10x the current market cap. and the P3 is fully funded SLS has $68M in Cash / $6.7M q Burn / runway into 2027 - no Offerings needed /Allowed per S3 through Jan.
0 · Reply
ReapN
ReapN Oct. 24 at 4:03 PM
$SLS setting up comparison $CPXX Celator $JAZZ M&a Celator who is SEllas suitoR(s)? Add low Hold Sell when its time
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 23 at 6:19 PM
$SNDX FY2026 & 10-year revenue multiple versus all commercial-stage oncology focused bios with market caps over $1.0B. SNDX's cumulative 10-year analyst revenue estimate excludes the highest revenue forecast for all 10-years. Using actual analyst consensus, SNDX trades at 0.12X 10-year revenues. Valuations use intra-day share prices on 10/23/2025 $IBRX trades at the 2nd lowest multiple. However, we understand IBRX needs future clinical wins to realize those estimates. We are not 100% certain $PGEN belongs in this peer group. Any suggestions would be welcome. $JAZZ multiples use enterprise value. $NVCR also appears a value using analyst estimates & multiples versus peers. We understand ST users express doubts on whether analyst estimates are credible in light of lung related sales to date. This is not investment advice.
3 · Reply
Quantumup
Quantumup Oct. 22 at 7:09 PM
RBC Capital⬆️ $ALKS's PT to $ 47 from $45, reiterated at Outperform, and said, Following the announcement of ALKS's intention to acquire $AVDL, we had the chance to catch up with ALKS mgmt. $JAZZ $CNTA $AXSM RBC Capital added: We think the acquisition checks multiple boxes — supporting a key future growth driver with a commercial base of operations, bringing in near-term revenues, and not stretching the balance sheet — and we think bringing in AVDL should strengthen both the near- and mid-term outlook for ALKS. We continue to like the setup into VIBRANCE-2 where we see potential for high efficacy and good tolerability, and with the base business performing well, and a new growth driver added, we would be buyers at these levels; price target to $47.X on model updates as we integrate AVDL.
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 22 at 12:50 PM
$AVDL (+3.7% pre) Avadel settles with $JAZZ Jazz Pharma; agrees to be acquired by $ALKS Alkermes https://ooc.bz/l/81384
0 · Reply
Rekin_rouge
Rekin_rouge Oct. 22 at 11:58 AM
$AVDL It’s the end of the journey for $AVDL. Learned a lot from this one — got in around $2.2 back then. Was already out before today, but still a bit disappointed by the takeover price and the weak JAZZ settlement. Expected a real hit for $JAZZ and $AVDL to run toward $40. Anyway, it’s been a ride.
1 · Reply
CUBBY91
CUBBY91 Oct. 21 at 5:37 PM
$JAZZ big volume today and a really nice technical set up. is there any news?
0 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 3:36 PM
Morgan Stanley has adjusted their stance on Jazz Pharmaceuticals ( $JAZZ ), setting the rating to Overweight with a target price of 167 → 180.
0 · Reply
twiggs462
twiggs462 Oct. 19 at 12:56 AM
$ATAI $MNMD Remember that $JAZZ bought our $GWPH in 2021 for 7.2B for their epilepsy drug Epidiolex. I realize that ATAI wants to run on their own, but its always possible for them to partner and get in lock step with a big player. Both them and MindMed could get bought out.
1 · Reply
Its_Only_Money_369
Its_Only_Money_369 Oct. 17 at 10:37 PM
$AVDL $JAZZ Since yaho wont let me post it and Jazz board will bury it with 10x average message volume ill post it here. If I were representing Avadel I would subpoena someone from each of the following. FDA, FTC, DOJ and Missouri Attorney Generals office. Not just because they would provide valuable testimony but because I’m sure some of them already have reserved seats. It would also prevent them from turning a blind eye to the issues they are obligated to oversee and address. Win or lose, the best angle for Avadel would be to make sure lack of oversight by those agencies is not an option. Multiple antitrust claims and at least one settlement outside of court involving Jazz monopolistic approach to Oxybate.
2 · Reply
Its_Only_Money_369
Its_Only_Money_369 Oct. 17 at 10:34 PM
$AVDL $JAZZ A civil victory by jury would be a slam dunk for Avadel in this scenario opening an easy victory for any of the mentioned agencies to force Jazz to dissolve the Oxybate portion of their business in the future. I’m sure Jazz is willing to settle for anything less. However I don’t believe Avadel will settle for anything less outside of the courtroom. As a defendant I once had an attorney ask what I wanted. My response was that I didn’t care about the money, I wanted people to stop ******* with me. Took it all the way without a *** 2 **** n and came out smelling like a rose. Avadel would be foolish to settle outside of court!
0 · Reply
Mandalo
Mandalo Oct. 16 at 4:30 PM
$MIRA Say $JAZZ to the future 🤑😎 🚨🚀🌡⚡️
0 · Reply
Quantumup
Quantumup Oct. 10 at 11:47 AM
Needham⬆️the PT on $STOK to $35 from $22 and reiterated at a Buy rating after STOK presented new zorevuneren OLE data in Dravet Syndrome (DS) at the 54th Child Neurology Society (CNS) annual meeting yesterday. [ $BIIB ] $JAZZ $UCBJY $UCBJF Needham said in its note: The new data showed 1) patients treated with zorevunersen had continued improvements in clinical outcomes through 3 years, and 2) an analysis of patients in the OLE who received a similar dosing regimen as the ongoing Ph3 trial continued to show improvements in the Vineland-3 (cognition & behavior) at 2 years vs. a DS natural history study. This new data, along with the positive 3-year OLE data shared in early August (see our note here), has increased our confidence in the long-term efficacy & durability of zorevunersen and the potential for significant differentiation (disease modification) over SoC anti-seizure drugs for the treatment of DS. We are raising our PT to $35 (was $22).
0 · Reply
paul8
paul8 Oct. 7 at 9:13 PM
$JAZZ Trump touts CBD and this is only FDAapproved CBD in world.
0 · Reply
va4f6
va4f6 Oct. 7 at 7:23 PM
$IXHL $IXHL REPOSA Advisory Board of 7 doctors include THREE Big Pharma (OSA) specialists from $NVO $RMD $JAZZ so of course the REPOSA Phase 2 results were outstanding with NO side effects!! CEO has 3 Big Pharma's helping to deliver REPOSA to the US Market! Phase 2 was a game changer!!!
0 · Reply
Quantumup
Quantumup Oct. 6 at 2:06 PM
Piper Sandler reit'd $ALKS OW-$38 and said: We caught up with Alkermes senior management as part of investor meetings that we hosted in Europe. $CNTA $AXSM $JAZZ $AVDL As we move closer to results from the Phase II Vibrance-2 study in narcolepsy type 2 (NT2) for orexin 2 receptor (OX2R) agonist alixorexton sometime in November (per management expectations), we provide herein a few brief thoughts on what we believe would count as a "win" from the trial. We continue to believe that the underlying size of the treated narcolepsy (narcolepsy type 1 (NT1) and NT2 combined) and idiopathic hypersomnia (IH) populations translates into ample room for a handful of novel OX2R agonists to readily coexist. Beyond that, opportunities for the category beyond sleep/wake are very much under the broader investor radar, though we would keep in mind that visibility into these opportunities (e.g., psychiatric indications) should improve over the next 12-18 months. We reiterate our Overweight rating and $38 PT.
0 · Reply
Jack_Mehoff42069
Jack_Mehoff42069 Oct. 5 at 2:19 AM
0 · Reply
NOOBofNASDAQ
NOOBofNASDAQ Oct. 5 at 1:22 AM
0 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 5:48 AM
$JAZZ: Unusual Options Activity Alerted CALL flow observed 101x contracts at Strike price of $135 Exp on 10/17/2025 with Premium of $45K and showing BEARISH Sentiment
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 3 at 10:09 AM
WATCHLIST OCT 03 2025. $NFLX Netflix shares are trading lower amid continued weakness possibly after Elon Musk recently called on followers to cancel their Netflix streaming subscriptions. $CANG Cango Inc. Announces September 2025 Bitcoin Production Of 616.6 BTC With 20.55 BTC Per Day Average Output $RIOT Northland Capital Markets Maintains Outperform on Riot Platforms, Raises Price Target to $24.5 $QNTM Quantum Biopharma shares are trading higher after the company announced it received two key final reports related to its potential breakthrough drug for Multiple Sclerosis. $JAZZ FDA Approves Lurbinectedin In Combination With Atezolizumab Or Atezolizumab And Hyaluronidase-tqjs For Extensive-Stage Small Cell Lung Cancer
0 · Reply
jaydjones82
jaydjones82 Oct. 3 at 1:13 AM
$JAZZ so great news came out about their drug receiving FDA approval and it dropped?
0 · Reply
julianbase23
julianbase23 Oct. 2 at 9:34 PM
$JAZZ why’s it down $7?
0 · Reply